Why the SmartDose 3.5mL sale matters for West Pharmaceutical Services stock

West Pharmaceutical Services (WST) has completed the sale and transfer of manufacturing and supply rights for its SmartDose 3.5mL On Body Delivery System and related facilities to AbbVie, refocusing attention on its core drug delivery offerings.

At a share price of $353.71, West Pharmaceutical Services has recently given up some ground with a 1-day share price return that declined 1.1% and a 7-day share price return that fell 3.3%. However, the 90-day share price return of 37.9% and 1-year total shareholder return of 56.2% point to strong momentum that contrasts with weaker 3 and 5-year total shareholder returns.

If the SmartDose news has you thinking about where drug delivery and treatment technology could head next, it may be worth scanning 41 healthcare AI stocks.

After the SmartDose 3.5mL sale and a strong 1 year share price run, the question for West Pharmaceutical Services is whether current levels justify investing now, or if waiting for a better entry looks more sensible as valuation is weighed next.

Most Popular Narrative: 1.4% Undervalued

The most followed narrative currently places West Pharmaceutical Services' fair value at $358.79, just above the last close of $353.71. This keeps attention firmly on what is baked into expectations rather than on a big valuation gap.

The continued growth in GLP-1s, which made up about 7% of total revenues in the first quarter, and the company's ability to capitalize on significant opportunities in this market could drive revenue and earnings growth. The increase in demand and the transition to higher-margin HVP components, supported by approximately 340 Annex 1 projects, is likely to positively impact both revenue and net margins due to a favorable mix shift.

Want to see what underpins that fair value uplift for West Pharmaceutical Services? The narrative leans on steadier top line growth, rising margins, and a richer future earnings multiple. Curious which assumptions really move the needle in that model and how long they are expected to hold?

The narrative uses a discount rate of 7.88% and builds in moderate revenue expansion, firmer profitability, and a future P/E that sits below some current sector metrics. Together these inputs support a fair value only slightly above where the stock trades today.

Result: Fair Value of $358.79 (UNDERVALUED)

However, West Pharmaceutical Services still faces potential pressure if demand for high value components shifts between sites or if higher tariffs increase costs more than expected.

Another view on West Pharmaceutical Services' valuation

The first narrative frames West Pharmaceutical Services as only modestly undervalued, but the earnings based multiple tells a very different story. At a P/E of 46x versus a fair ratio of 22.3x, the stock trades at roughly double the level the market could move toward. It also sits above peer averages of 28.9x and a global industry average of 36.2x. Is that premium a margin of safety in quality, or valuation risk if expectations soften?

To see how that premium stacks up against peers and where the fair ratio might point next, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the mixed signals around West Pharmaceutical Services so far, it makes sense to check the underlying data yourself and decide quickly where you stand. To see what investors are finding encouraging about the company right now, review the 2 key rewards

Looking for more investment ideas beyond West Pharmaceutical Services?

If West Pharmaceutical Services has sparked fresh thinking about your portfolio, do not stop here. Broaden your opportunity set with a few focused stock idea lists.

• Target quality at a discount by scanning 44 high quality undervalued stocks that combine solid fundamentals with pricing that may not fully reflect them.
• Strengthen your income stream by reviewing 9 dividend fortresses built around higher yielding companies with an emphasis on resilience.
• Dial down portfolio stress by considering 76 resilient stocks with low risk scores that aim to keep business and balance sheet risks in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.